MBX Biosciences, Inc. Common Stock
MBX
Updated: 25/09/2026, 16:00:46
MBX Biosciences, Inc. is a biopharmaceutical company in its clinical development phase, dedicated to pioneering precise peptide-based therapies for endocrine and metabolic conditions. Its most advanced drug candidate, MBX 2109, is a parathyroid hormone peptide prodrug currently in Phase 2 clinical trials. This medication is being evaluated as a long-duration hormone replacement treatment for individuals suffering from chronic hypoparathyroidism. The company is also progressing with MBX 1416, a prolonged-action glucagon-like peptide-1 (GLP-1) receptor antagonist, which is undergoing Phase 1 clinical assessment. The aim of this therapy is to address post-bariatric hypoglycemia, a persistent complication often seen after weight-loss surgery. Furthermore, MBX Biosciences is developing MBX 4291, a key candidate for obesity treatment. This highly potent and long-acting prodrug functions as a co-agonist for both GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptors. It is currently in investigational new drug (IND)-enabling studies, with the intention of treating obesity and its associated health issues. Founded in 2018, the company's operations are headquartered in Carmel, Indiana.
No summaries found.
- Share price
- $53.94
- Market cap
- $2.57B
- Exchange
- NASDAQ
- Currency
- USD
- CEO
- Steve Hoerter
- Employees
- 63
- IPO date
- 13/09/2024
- Beta
- 0.09918355
- Last dividend
- $0.00
- Day range
- $53.73 – $56.00
- 52-week range
- $12.94 – $72.64
- 1-day performance
- -2.63%
- 1-year performance
- 316.81%
- Current drawdown (1Y)
- -25.75%
- CIK
- 0001776111
- CUSIP
- 55287L101
- ISIN
- US55287L1017
- Created
- 07/12/2025, 05:10:48
- Last update
- 25/09/2026, 16:00:46
Track MBX Biosciences, Inc. Common Stock with an AI analyst
See which prediction-market events move MBX, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.
Free forever to follow AlphaBrain’s AI strategies. No card required.
MBX Biosciences, Inc. (MBX) Discusses One-Year Data From Phase II Open-Label Extension Study of Once-Weekly Canvuparatide Transcript
Seeking Alpha • STOCK • 12/06/2026, 16:32:09
MBX Biosciences Announces One-Year Data Demonstrating Sustained Benefit of Once-Weekly Canvuparatide as a Potential PTH Replacement Therapy in Chronic Hypoparathyroidism
GlobeNewsWire • STOCK • 12/06/2026, 09:00:00
MBX Biosciences to Host Virtual Investor Event to Discuss Once-Weekly Canvuparatide Presentations at ENDO 2026
GlobeNewsWire • STOCK • 01/06/2026, 10:00:00
MBX Biosciences, Inc. (MBX) Discusses Novel Approaches and Clinical Progress in Obesity Therapeutics Portfolio Transcript
Seeking Alpha • STOCK • 11/05/2026, 22:10:44
MBX Biosciences Obesity Day Spotlights Monthly GLP-1 Hope and Pipeline Push
MarketBeat • STOCK • 11/05/2026, 17:09:21
Microbix Product Results Being Presented at 2026 PASCV
Accesswire • STOCK • 27/04/2026, 09:00:00
Microbix Presenting at the 2026 Bloom Burton Conference
Accesswire • STOCK • 16/04/2026, 09:00:00
MBX Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewsWire • STOCK • 03/04/2026, 10:00:00
CORRECTING & REPLACING -- MBX Biosciences Announces Successful End-of-Phase 2 FDA Meeting and Provides Phase 3 Development Plan for Once-Weekly Canvuparatide for Hypoparathyroidism
GlobeNewsWire • STOCK • 09/03/2026, 11:21:00
MBX Biosciences to Participate in Upcoming March Investor Conferences
GlobeNewsWire • STOCK • 23/02/2026, 09:00:00